TAK-279 Study for Plaque Psoriasis

This research is about finding out how safe and tolerable a new medicine called TAK-279 is for people with moderate-to-severe plaque psoriasis, a skin condition that causes red, scaly patches. Everyone in the study will receive TAK-279.

Participants will be involved for up to 217 weeks, which includes a screening period, treatment in two parts, and a follow-up period. You will need to visit the clinic several times during the study.

• The study is in two parts: Part A lasts 52 weeks, and Part B can last up to 156 weeks.
• Part A is for new participants, while Part B is for those who complete Part A or other related studies.
• Participants must be over 18 and have moderate-to-severe plaque psoriasis for at least 6 months.

Considerations: Before joining, check if you meet the requirements and consider the long commitment and multiple clinic visits. Always discuss potential risks and benefits with your doctor.